Current indications for prevention and therapy of steroid-induced osteoporosis in men and women

Endokrynologia Polska

Volumn 62, Issue 1, 2011, Pages 38-44

  Sewerynek, Ewa ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Men; Prevention; Steroid induced osteoporosis; Treatment; Women

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BECLOMETASONE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; CORTICOSTEROID; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADULT; BONE METABOLISM; CHILD; CLINICAL PRACTICE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DENSITOMETRY; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; FRACTURE; HUMAN; LIFESTYLE; LONG TERM CARE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RISK; VITAMIN INTAKE;

EID: 79953818917     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism) 1932. Obes Res 1994; 2: 486-508.
2. Hazard J. Discovery of mineralocorticoid hormones. Hist Sci Med 2004; 38: 441-448.
3. van der Laan S, Meijer OC. Pharmacology of glucocorticoids: beyond receptors. Eur J Pharmacol 2008; 585: 483-491.
4. Stahn C, Lowenberg M, Hommes DW et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-78. (Pubitemid 47259281)
5. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93: 105-111. (Pubitemid 30098773)
6. Sewerynek E, Bajon K, Stuss M. Osteoporoza wtórna w przebiegu przewlekłej steroidoterapii. Przegla̧d Menopauzalny 2007: 336-344.
7. Sewerynek E, Stuss M. Farmakologiczna prewencja osteoporozy. Terapia 2008; 5: 1-9.
8. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-1328.
9. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010; 6: 82-88.
10. Jehle PM. Steroid-induced osteoporosis: how can it be avoided? Nephrol Dial Transplant 2003; 18: 861-864.
11. Natsui K, Tanaka K, Suda M et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006; 17: 105-108. (Pubitemid 41798034)
12. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-899. (Pubitemid 41103445)
13. Angeli A, Guglielmi G, Dovio A et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39: 253-259. (Pubitemid 43870263)
14. van Staa TP, Leufkens HG, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 2002; 13: 624-629.
15. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-787. (Pubitemid 36336722)
16. van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383-1389. (Pubitemid 32045866)
17. van Staa TP, Dennison EM, Leufkens HG et al. Epidemiology of fractures in England and Wales. Bone 2001; 29: 517-522.
18. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000. (Pubitemid 30350061)
19. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004; 15: 323-328. (Pubitemid 38543952)
20. Kanis JA, McCloskey EV, Johansson H et al. Case finding for the management of osteoporosis with FRAX -assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19: 1395-1408.
21. Kanis JA, Oden A, Johansson H et al. FRAX and its applications to clinical practice. Bone 2009; 44: 734-743.
22. Nguyen ND, Frost SA, Center JR et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2007; 18: 1109-1117. (Pubitemid 47020008)
23. Nguyen ND, Frost SA, Center JR et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008; 19: 1431-1444.
24. Pluskiewicz W, Adamczyk P, Franek E et al. Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al. - Conformity between methods and their clinical utility. Bone 2010; 46: 1661-1667.
25. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002; 61: 32-36. (Pubitemid 34074836)
26. Ardizzone S, Puttini PS, Cassinotti A et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008; 40 (Suppl. 2): S253-S259. (Pubitemid 351878068)
27. Decramer M, Rennard S, Troosters T et al. COPD as a lung disease with systemic consequences - clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5: 235-256.
28. Katz S. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment. Rev Gastroenterol Disord 2006; 6: 63-71. (Pubitemid 43826897)
29. Vestergaard P. Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy. Curr Drug Saf 2008; 3: 168-172.
30. Allen DB, Bielory L, Derendorf H et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112: S1-S40. (Pubitemid 37108545)
31. Wong CA, Walsh LJ, Smith CJ et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355: 1399-1403. (Pubitemid 30215962)
32. Sewerynek E. Stosowanie steroidów wziewnych w terapii dróg oddechowych - powikłania i metody diagnozowania. Alergia 2010; 4: 1-7.
33. Ledford D, Apter A, Brenner AM et al. Osteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol 1998; 102: 353-62. (Pubitemid 28471491)
34. Curtis JR, Westfall AO, Allison JJ et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005; 52: 2485-2494. (Pubitemid 41117436)
35. Feldstein AC, Elmer PJ, Nichols GA et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005; 16: 2168-2174. (Pubitemid 41790940)
36. Blalock SJ, Norton LL, Patel RA et al. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005; 53: 732-739.
37. Bobba R, Adachi JD. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging 2007; 2: 275-282.
38. Orwoll E, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
39. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17. (Pubitemid 36008334)
40. Czerwiński E, Bandurski J, Marcinowska-Suchowierska G et al. Współczesne rozumienie osteoporozy w świetle stanowiska World Health Organization (WHO) i International Osteoporosis Foundation (IOF). Ortop Traumat Rehab 2007; 9: 337-356. (Pubitemid 351145441)
41. Compston J. US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep 2004; 6: 66-69.
42. Compston JE. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr Rheumatol Rep 2007; 9: 78-84. (Pubitemid 46806312)
43. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 2001; 44: 1496-1503.
44. Solomon DH, Katz JN, Jacobs JP et al. Management of glucocorticoid- induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002; 46: 3136-3142. (Pubitemid 35453521)
45. Lorenc RS, Głuszko P, Kaczmarewicz E et al. Zalecenia postȩpowania diagnostycznego i leczniczego w osteoporozie. Obnizenie czȩstości złamán poprzez efektywna̧ profilaktykȩ i leczenie. Terapia 2007; 9: 11-39.
46. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1-S34. (Pubitemid 35365303)
47. Devogelaer JP, Goemaere S, Boonen S et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006; 17: 8-19. (Pubitemid 41798023)
48. Geusens PP, Lems WF, Verhaar HJ et al. Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 2006; 12: 539-548. (Pubitemid 44427286)
49. Nawata H, Soen S, Takayanagi R et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005; 23: 105-109.
50. van Staa TP LHCC. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581-588.
51. Compston J, Reid DM, Boisdron J et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 2008; 19: 1247-1250.
52. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-387. (Pubitemid 27328368)
53. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-211. (Pubitemid 32113136)
54. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309-2318.
55. Herrala J, Puolijoki H, Impivaara O et al. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone 1994; 15: 621-623. (Pubitemid 24332653)
56. Ringe JD, Dorst A, Faber H et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801-807. (Pubitemid 37462129)
57. Ing-Lorenzini K, Desmeules J, Plachta O et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009; 32: 775-785.
58. Khan AA, Sandor GK, Dore E et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36: 478-490.
59. Homik J, Suarez-Almazor ME, Shea B et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000: CD000952.
60. Lambrinoudaki I, Chan DT, Lau CS et al. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27: 1759-1765. (Pubitemid 30462824)
61. Sambrook P, Henderson NK, Keogh A et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15: 1818-1824. (Pubitemid 30666235)
62. Sambrook P, Birmingham J, Kelly P et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747-1752. (Pubitemid 23170124)
63. Stempfle HU, Werner C, Echtler S et al. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 1999; 68: 523-530. (Pubitemid 29416628)
64. Lakatos P, Nagy Z, Kiss L et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59 (Suppl. 1): 48-52.
65. Reginster JY, Kuntz D, Verdickt W et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9: 75-81. (Pubitemid 29086167)
66. Ringe JD, Coster A, Meng T et al. Treatment of glucocorticoid-induced osteoporosis with alfacalcidoVcalcium versus vitamin D/calcium. Calcif Tissue Int 1999; 65: 337-340. (Pubitemid 29471017)
67. Ringe JD, Faber H, Fahramand P et al. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol 2005; 76 (Suppl.): 33-40. (Pubitemid 41324842)
68. de Nijs RN, Jacobs JW, Lems WF et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355: 675-684.
69. Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919-924. (Pubitemid 37294977)
70. Prophylaxis of vitamin D deficiency - Polish Recommendations 2009. Pol J Endocrinol 2010; 2: 228-232.
71. Marcinowska-Suchowierska E, Walicka M, Talataj M et al. Vitamin D supplementation in adults - guidelines. Pol J Endocrinol 2010; 6: 723-729.
72. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol 2007; 26: 144-153. (Pubitemid 46020234)
73. Cranney A, Welch V, Adachi JD et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000: CD001983.
74. Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 2007; 40: 1447-1452. (Pubitemid 46756408)
75. Lane NE, Sanchez S, Modin GW et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-1633. (Pubitemid 28492231)
76. Lane NE, Sanchez S, Modin GW et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15: 944-951. (Pubitemid 30233419)
77. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039. (Pubitemid 350106710)
78. Langdahl BL, Marin F, Shane E et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20: 2095-104.
79. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60: 3346-3355.
80. Burshell AL, Moricke R, Correa-Rotter R et al. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010; 46: 935-939.
81. Eastell R, Chen P, Saag KG et al. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010; 46: 929-934.
82. Mazziotti G, Angeli A, Bilezikian JP et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006; 17: 144-149.
83. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006; 443: 39-47.
84. Curtis JR, Westfall AO, Allison JJ et al. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006; 17: 1268-1274.
85. Newman ED, Matzko CK, Olenginski TP et al. Glucocorticoid-induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006; 17: 1428-1434. (Pubitemid 44127331)
86. van Staa TP, Geusens P, Zhang B et al. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 2007; 46: 460-466. (Pubitemid 46344659)